mTNX-1700 (mTFF2-MSA) suppresses tumor growth and increases survival rates in preclinical colorectal cancer models mTNX-1700 shows single agent activity and additive effects in combination with anti-PD-1 mTNX-1700 targets myeloid-derived suppressor cells (MDSCs) in a novel mechanism to treat cancer CHATHAM, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, today
Tonix Pharmaceuticals Presents New Preclinical Data At Seventh International Cancer Immunotherapy Conference 2023 menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.